Cargando…
Improved targeting of an anti‐TAG‐72 antibody drug conjugate for the treatment of ovarian cancer
INTRODUCTION: Ovarian cancer has only a 17% 5‐year survival rate in patients diagnosed with late stage disease. Tumor‐associated glycoprotein‐72 (TAG72), expressed in 88% of all stages of ovarian cancer, is an excellent candidate for antibody‐targeted therapy, as it is not expressed in normal human...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333846/ https://www.ncbi.nlm.nih.gov/pubmed/32368864 http://dx.doi.org/10.1002/cam4.3078 |